What can we learn from Idiopathic Pulmonary Fibrosis Registries?

Conclusion: Our patients present years after becoming symptomatic, with significant lung function impairment and co-morbidities. 69% of our patients are prescribed antifibrotics which is higher than published uptake in Europe and the US. Our registry provides insights into the diagnosis and management of IPF patients in the real-world setting.

http://erj.ersjournals.com/cgi/content/short/52/suppl_62/PA2195?rss=1

Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Lodhi, T., Leonard, C., Rivera Ortega, P., Morris, H., Marshall, T., Zakis, K., Garfoot, T., Hayton, C., Greaves, M., Blaikley, J., Chaudhuri, N. Tags: Idiopathic interstitial pneumonias Source Type: research